Power wheelchair — group 2 denied due to quantity / dose limits by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## UnitedHealthcare Group 2 Power Wheelchair Denials — Quantity Limits

Quantity-limit denials on K0820–K0829 from UnitedHealthcare almost always invoke one of three triggers buried inside the Mobility Devices, Options, and Accessories Commercial Medical Policy: (1) the 5-year Reasonable Useful Lifetime (RUL) baked into the policy and inherited from CMS LCD L33789, (2) the "one wheelchair at a time" rule that rejects backup or secondary chairs as not reasonable and necessary, or (3) a per-code frequency cap mirrored from the DME MAC Policy Article (replacement components billed inside the RUL window without K0462 loaner justification). Optum administers the DME benefit on the back end for most UHC commercial plans, and the denial code typically reads CO-151 (information submitted does not support frequency) rather than a true medical-necessity denial — this distinction matters because the appeal posture is procedural, not clinical.

The RUL clock runs from initial date of delivery, not the date of purchase order. If you are inside 5 years, the only viable paths are (a) irreparable damage (supplier must produce a written repair estimate exceeding 60% of replacement cost, plus photos), (b) change in beneficiary's medical condition requiring a different base code (e.g., progression from K0823 to K0835 Single Power Option following documented loss of upper-extremity proportional control), or (c) loss/theft with police report. UHC will not waive RUL on convenience or cosmetic grounds, and Optum reviewers are explicit about that on peer-to-peer.

The backup-chair denial is the harder fight. UHC reads CMS guidance strictly: one PMD per beneficiary, period. The exception that actually works is documenting that the patient requires two distinct mobility configurations for separable MRADL environments — for example, a Group 2 PWC for in-home MRADLs paired with a separately-coded manual transport chair (E1038) for vehicle transfer. Frame it as complementary equipment, not redundancy.

For commercial plans, you have 180 days under 29 CFR §2560.503-1 for the internal ERISA appeal and full claim-file access on request. Demand the ATP evaluation, the specialty LCMP evaluation, the supplier's RUL attestation, and the Optum reviewer notes — Optum frequently denies on assumptions that the ATP eval was missing when it was simply not forwarded. For Medicare Advantage members, escalate under 42 CFR §422.566 with a 60-day window and push to the Part C IRE (MAXIMUS) if the plan affirms. Wit v. UBH (9th Cir. 2023) is not directly on point for DME but its holding — that plans cannot apply internal criteria more restrictive than generally accepted standards — has been cited successfully against Optum when UHC's quantity rules exceed CMS LCD L33789.

Tactical tip: Before filing the appeal, call Optum DME prior-auth at 877-842-3210 and request the specific Coverage Summary version and policy effective date used for the denial. Quantity-limit policies are revised quarterly; if the supplier's claim was adjudicated under a superseded version, that alone is grounds for reversal on the first-level appeal without engaging the clinical merits.